Welcome to our dedicated page for IceCure Medical news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on IceCure Medical stock.
IceCure Medical Ltd. develops and markets liquid-nitrogen-based cryoablation systems for minimally invasive tumor destruction. Its flagship ProSense® system is used for benign and cancerous lesions, with company updates centered on breast, kidney, bone and lung cancer indications and on markets where the device is cleared or approved, including the United States, Europe and Asia.
News about ICCM commonly covers ProSense commercialization, FDA-related breast cancer developments, post-market study activity, clinical evidence such as the ICESECRET kidney cancer study, medical-conference presentations, financial and operating results, and governance changes. The company’s updates also address physician training, reimbursement context and shareholder matters tied to its ordinary shares.
IceCure Medical (Nasdaq: ICCM) announced publication in PLOS One of an independent study showing ProSense® cryoablation is safe and effective for breast fibroadenomas.
The study reported a median volume reduction of 80.6% at ~6 months and 92.9% at one year, evaluated larger lesions using up to three cryoprobe relocations, and notes ProSense® has FDA clearance for fibroadenomas.
IceCure Medical (Nasdaq: ICCM) completed five-year follow up for its ICESECRET kidney cancer trial of ProSense, covering 114 patients and 138 lesions.
Interim three-year data from 111 patients showed an 88.7% recurrence-free rate. ProSense is approved for kidney tumors in the U.S., Europe and other countries; final analysis is expected in Q2 2026.
IceCure (NASDAQ: ICCM) announced that Thomas Hospital of Fairhope, part of Infirmary Health, purchased and installed the ProSense® cryoablation system, becoming the first hospital in Alabama to offer breast cancer cryoablation. Procedures are scheduled to begin in the coming weeks, funded by the Thomas Hospital Foundation. The move follows the October 2025 FDA clearance for local treatment of low-risk breast cancer and growing clinical interest.
IceCure Medical (NASDAQ: ICCM) announced that Shero Imaging in St. Louis, Missouri is the first clinic in the state to offer breast cancer cryoablation using the ProSense® system. The release notes FDA marketing authorization for ProSense® for low-risk breast cancer and inclusion in proposed medical society guidelines for the approved population. Procedures at Shero Imaging will be performed by founder and board-certified breast radiologist Dr. Tish Singer, expanding local patient access to a minimally invasive alternative to surgical tumor removal.
IceCure (Nasdaq: ICCM) announced on Feb. 9, 2026 that Chief Financial Officer Ronen Tsimerman will depart after nearly nine years to pursue new opportunities but will remain in his role until a successor is appointed to ensure a smooth transition.
The company has launched a CFO search and reports several compelling candidates advancing to board interviews. Management credited Tsimerman with helping achieve key milestones, including the Nasdaq listing, fundraisings to complete the ICE3 study, and U.S. FDA marketing clearance of ProSense® for low-risk breast cancer in late 2025.
IceCure (Nasdaq: ICCM) announced the American Society of Breast Surgeons' draft update to its resource guide would include cryoablation for select low‑risk breast cancer patients, aligning with the FDA's October 2025 marketing authorization. The draft covers patients ≥70 with ≤1.5 cm biologically low‑risk tumors and recommends cryoablation for fibroadenomas.
IceCure cited its ICE3 trial (5‑year local recurrence 3.1%) and reported growing U.S. commercial interest and installed systems across North America. The ASBrS comment period closed January 23, 2026; finalization is pending.
Apartment Investment and Management Company (NYSE: AIV) disclosed the federal tax character of its 2025 distributions to Class A common stockholders. Aimco reported total 2025 distributions of $2.83 per share, which the company allocated as 100.00% total capital gain and 0.00% ordinary dividends. The company disclosed an unrecaptured Sec. 1250 gain of ~33.7355% and Section 897 capital gain 100.00% for the distributions. Aimco noted its 2025 tax return has not yet been filed and the allocation is based on the best available information. Aimco also referenced its announced Plan of Sale and Liquidation and a Definitive Proxy Statement filed January 2, 2026, in connection with a forthcoming stockholder vote.
IceCure (Nasdaq: ICCM) reported record 2025 ProSense® sales of approximately $3.4 million and cash and cash equivalents of approximately $8.9 million as of December 31, 2025, based on preliminary unaudited estimates. In October 2025 the company received FDA marketing authorization for ProSense® for local treatment of low-risk breast cancer in women aged 70+ with endocrine therapy, making it the first and only device with that FDA authorization. The company reported record European sales, expanded scientific publications and presentations, four new U.S. and China patents, and reimbursement under CPT III at $4,049 effective January 2026.
IceCure (NASDAQ: ICCM) expects record fourth quarter North American sales driven by increased orders and installations of its ProSense® cryoablation system following the FDA marketing authorization in October 2025 for local treatment of low-risk breast cancer in women aged 70 and above. The company reports rapid interest from hospitals, breast surgeons and radiologists, including orders from a highly ranked U.S. hospital network, and says ProSense® is receiving broad media and conference visibility. IceCure plans preliminary top-line revenue disclosure in January 2026 and its full Form 20-F in April 2026.
IceCure (NASDAQ: ICCM) reported that four independent abstracts featuring its ProSense cryoablation system were presented at RSNA 2025 (Nov 30–Dec 4, 2025).
Key data from three studies covering 263 patients include: 100% success for luminal cancers ≤2.5 cm, complete necrosis 81.2% in a 73‑patient cohort, Cryoablation+HT tumor reduction 83.3% (mean 13.6 mm) versus HT‑only 42.1%, and CEM showing NPV and sensitivity 100% for cryoablation assessment. The company noted growing adoption following the FDA marketing approval for low‑risk breast cancer.